All In Biotech

Drug Trial Radar · NCT05430919

Efficacy of the Anti-Bet v 1 Monoclonal Antibodies (Given Subcutaneously) to Reduce Allergic Rhinitis and Conjunctivitis Symptoms and Skin Test Reactivity Upon Exposure to Birch Allergen in Adult Participants

A Two-Part Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy of the Anti-Bet v 1 Monoclonal Antibodies to Reduce Allergic Rhinitis and Conjunctivitis Symptoms and Skin Test Reactivity Upon Exposure to Birch Allergen

Last checked: Nov 19, 2026Latest source record: Nov 19, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 217 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

217

Actual

Start

Aug 15, 2022

Primary completion

Jul 31, 2023

Study completion Jul 31, 2023

Sponsor

Lead sponsor
Regeneron PharmaceuticalsRegeneron (REGN)
Sponsor type
Industry
First posted
Jun 24, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Primary objective: To assess the efficacy of a single dose of the anti- Bet v 1 monoclonal antibodies (mAb(s ) in the reduction of allergic nasal symptoms during an out-of-season birch allergen environmental exposure unit (EEU) challenge in participants receiving REGN5713-5714-5715 versus placebo (Part A)

Conditions

  • Allergic Rhinitis
  • Conjunctivitis

Interventions

  • REGN5713Drug

    Administered subcutaneously (SC)

  • REGN5714Drug

    Administered SC

  • REGN5715Drug

    Administered SC

  • PlaceboOther

    Administered SC

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean Total Nasal Symptom Score (TNSS) (2 to 6 Hours) During Out-of-season Birch Allergen Environmental Exposure Unit (EEU) Challenge (REGN5713-5714-5715 vs. Placebo) at Day 29Time frame: Day 29 from randomization (Out-of-season)

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Kingston General Health Research Institute

    Kingston, Ontario, Canada

  • Inflamax Research Limited DBA Cliantha Research

    Mississauga, Ontario, Canada

  • Clinique Specialisee en Allergie de la Capitale

    Québec, Quebec, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.